Skip to main content
UCB's Global Corporate Website
instagram
facebook
twitter
youtube
linkedin
rss
Listen
16 Oct 2021
Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab
Read More
8 Oct 2021
Disposals of own shares
Read More
29 Sep 2021
New BIMZELX[®]▼ (bimekizumab) two-year data in moderate to severe plaque psoriasis presented at the 30th European Academy of Dermatology and Venereology (EADV) Congress
Read More
24 Sep 2021
Disposals of own shares
Read More
10 Sep 2021
Disposals of own shares
Read More
6 Sep 2021
BIMZELX[®]▼ (bimekizumab) Receives First Positive Health Technology Assessment Worldwide
Read More
3 Sep 2021
Transparency notification Wellington
Read More
3 Sep 2021
Disposals of own shares
Read More
27 Aug 2021
Disposals of own shares
Read More
27 Aug 2021
UCB showcases commitment to treatment and management of epilepsy at the 34th International Epilepsy Congress
Read More
Pagination
First page
Previous page
‹ Previous
Page
1
Page
2
Page
3
Current page
4
Page
5
Page
6
Page
7
Page
8
Page
9
…
Next page
Next ›
Last page
Subscribe to
Choose a Country
Global Site – English
Australia – English
België – Engels
Belgique – Anglais
Brasil – Português
България – Български
Canada – English
Canada – Français
中国 – 中文
Česká Republika – Angličtina
Danmark – Engelsk
Deutschland – Deutsch
France – Français
España – Español
Ελλάδα – Ελληνικά
India – English
Ireland – English
Italia – Inglese
日本 – 日本語
한국 – 한국어
Luxembourg – Anglais
Luxemburg – Engels
Magyarország – Angol
México & Latinoamérica – Español
Nederland – Engels
New Zealand – English
Norge – Engelsk
Österreich – Deutsch
Polska – Polski
Portugal – español y portugués
România – Engleză
Россия – Русский
Slovensko – Anglický
Suomi – Englanti
Sverige – Engelska
Schweiz – Deutsch
Türkiye – Türkçe
Україна – Англійська
United Kingdom – English
U.S.A. – English
×
instagram
facebook
twitter
youtube
linkedin
rss